Similar articles

• Protocol core needle biopsy and histological chronic allograft damage index as surrogate endpoint for Long-Term graft survival.

  Hayry P, Paavonen T, Taskinen E, Tomlanovich E, Mathew T, Navarro M, Ramos E, Hooftman L, Vamvakopoulos J, Aavik E, Yilmaz S. Hayry P, et al. Transplant Proc. 2004 Jan-Feb;36(1):89-91. doi: 10.1016/j.transproceed.2003.11.006. Transplant Proc. 2004. PMID: 15013309
• Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study.

  Campistol JM, Mazuecos A, Segura J, Osuna A, Herrero JC, Andres A, Oppenheimer F, Gomez de la Camara A, Martinez MA, Morales JM. Campistol JM, et al. Transplant Proc. 1999 Sep;31(6):2267-9. doi: 10.1016/s0041-1345(99)00332-2. Transplant Proc. 1999. PMID: 10500571 Clinical Trial. No abstract available.
• Mycophenolate mofetil (Cellcept) in renal transplantation: the European experience. The European Mycophenolate Mofetil Co-operative Study Group.

  Carl S, Wiesel M. Carl S, et al. Transplant Proc. 1997 Nov;29(7):2932-5. doi: 10.1016/s0041-1345(97)00734-3. Transplant Proc. 1997. PMID: 9365619 Clinical Trial. No abstract available.
• Protocol core biopsy as intermediate efficacy end-point in chronic kidney allograft rejection.

  Yilmaz S, Taskinen E, Häyry P, Isoniemi H. Yilmaz S, et al. Transplant Proc. 1996 Feb;28(1):491-3. Transplant Proc. 1996. PMID: 8644324 Review. No abstract available.
• The current status of mycophenolate mofetil in pediatric renal transplantation.

  Tönshoff B. Tönshoff B. Pediatr Transplant. 1999 Feb;3(1):5-9. doi: 10.1034/j.1399-3046.1999.00021.x. Pediatr Transplant. 1999. PMID: 10359025 Review. No abstract available.